Triple

Given a phrase, classify it is english named entity (e.g., persons, organizations, works of art) in Latin script, or not (e.g., literals, dates, URLs, verbose phrases). For disambiguation, the statement where the phrase occurs as object is also given. Please return a JSON object with `phrase` (string, the phrase being analyzed) and `is_ne` (boolean, indicating whether the phrase is a Named Entity).

Phrase: Human Fertilisation and Embryology Authority | Statement: [Department of Health and Social Care, oversees, Human Fertilisation and Embryology Authority]

Target entity: Human Fertilisation and Embryology Authority
Context triple: [Department of Health and Social Care, oversees, Human Fertilisation and Embryology Authority]

• A. Committee for Advanced Therapies
  The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
• B. UK Medicines and Healthcare products Regulatory Agency
  The UK Medicines and Healthcare products Regulatory Agency is the United Kingdom’s national authority responsible for regulating medicines, medical devices, and healthcare products to ensure their safety, quality, and effectiveness.
• C. Babraham Research Campus
  Babraham Research Campus is a major life sciences research and innovation hub near Cambridge, England, focused on bioscience, biotechnology, and academic–industry collaboration.
• D. Committee for Proprietary Medicinal Products
  The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
• E. Committee for Orphan Medicinal Products
  The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
• F. None of above. chosen
• G. Unsure - the case is ambiguous/there is not enough information to decide.

Generate a one-sentence description of the target entity. 
You are given a context triple in the form (subject, predicate, object), where the object is the target entity. 
# Instructions
Use the triple to infer relevant information about the entity. Describe the entity based on what is most defining, well-known. 
Avoid repeating the information from the triple, unless really essential.
# Response Format
Return only the sentence: "Description: [one-sentence description of the target entity]"

Entity: Human Fertilisation and Embryology Authority
Triple: [Department of Health and Social Care, oversees, Human Fertilisation and Embryology Authority]

The Human Fertilisation and Embryology Authority is the UK’s independent regulator overseeing fertility treatment and embryo research to ensure safety, ethical standards, and compliance with the law.

Target entity: Human Fertilisation and Embryology Authority
Target entity description: The Human Fertilisation and Embryology Authority is the UK’s independent regulator overseeing fertility treatment and embryo research to ensure safety, ethical standards, and compliance with the law.

• A. Committee for Advanced Therapies
  The Committee for Advanced Therapies is a scientific body within the European Medicines Agency responsible for evaluating and providing expert opinions on advanced therapy medicinal products such as gene, cell, and tissue-engineered therapies.
• B. UK Medicines and Healthcare products Regulatory Agency
  The UK Medicines and Healthcare products Regulatory Agency is the United Kingdom’s national authority responsible for regulating medicines, medical devices, and healthcare products to ensure their safety, quality, and effectiveness.
• C. Babraham Research Campus
  Babraham Research Campus is a major life sciences research and innovation hub near Cambridge, England, focused on bioscience, biotechnology, and academic–industry collaboration.
• D. Committee for Proprietary Medicinal Products
  The Committee for Proprietary Medicinal Products was a former scientific committee of the European Union responsible for evaluating and issuing opinions on the quality, safety, and efficacy of human medicinal products before it was replaced by the European Medicines Agency’s current committee structure.
• E. Committee for Orphan Medicinal Products
  The Committee for Orphan Medicinal Products is a specialized expert body that evaluates and advises on the designation and development of medicines for rare diseases within the European Union.
• F. None of above. chosen